References
1 Allen, TM. Ligand‐targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2: 750–763.
2 Liu, Y, Miyoshi, H, Nakamura, M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer 2007, 120: 2527–2537.
3 Boas, U, Heegaard, PM. Dendrimers in drug research. Chem Soc Rev 2004, 33: 43–63.
4 Agarwal, A, Saraf, S, Asthana, A, Gupta, U, Gajbhiye, V,
et al. Ligand based dendritic systems for tumor targeting. Int J Pharm 2008, 350: 3–13.
5 Agarwal, A, Asthana, A, Gupta, U, Jain, NK. Tumour and dendrimers: a review on drug delivery aspects. J Pharm Pharmacol 2008, 60: 671–688.
6 Cloninger, MJ. Biological applications of dendrimers. Curr Opin Chem Biol 2002, 6: 742–748.
7 Cheng, Y, Xu, Z, Ma, M, Xu, T. Dendrimers as drug carriers: applications in different routes of drug administration. J Pharm Sci 2008, 97: 123–143.
8 Dufès, C, Uchegbu, IF, Schätzlein, AG. Dendrimers in gene delivery. Adv Drug Deliv Rev 2005, 57: 2177–2202.
9 Gillies, ER, Frechet, JMJ. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005, 10: 35–43.
10 Lee, CC, MacKay, JA, Frechet, JMJ, Szoka, FC. Designing dendrimers for biological applications. Nat Biotechnol 2005, 23: 1517–1526.
11 Liu, M, Frechet, JM. Designing dendrimers for drug delivery. Pharm Sci Technol Today 1999, 2: 393–401.
12 Svenson, S, Tomalia, DA. Dendrimers in biomedical applications–reflections on the field. Adv Drug Deliv Rev 2005, 57: 2106–2129.
13 Svenson, S. Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm 2009, 71: 445–462.
14 Hong, S, Leroueil, PR, Majoros, IJ, Orr, BG, Baker, JR
Jr, et al. The binding avidity of a nanoparticle‐based multivalent targeted drug delivery platform. Chem Biol 2007, 14: 107–115.
15 Esfand, R, Tomalia, DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today 2001, 6: 427–436.
16 Kukowska‐Latallo, JF, Candido, KA, Cao, Z, Nigavekar, SS, Majoros, IJ,
et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005, 65: 5317–5324.
17 Kong, G, Braun, RD, Dewhirst, MW. Hyperthermia enables tumor‐specific nanoparticle delivery: effect of particle size. Cancer Res 2000, 60: 4440–4445.
18 Frechet, JMJ, Tomalia, DA, eds.
Dendrimers and Other Dendritic Polymers: Chichester, England:
Wiley; 2001.
19 Padilla De Jesus, OL, Ihre, HR, Gagne, L, Frechet, JM, Szoka, FC
Jr. Polyester dendritic systems for drug delivery applications:
in vitro and
in vivo evaluation. Bioconjug Chem 2002, 13: 453–461.
20 Morgan, MT, Carnahan, MA, Immoos, CE, Ribeiro, AA, Finkelstein, S,
et al. Dendritic molecular capsules for hydrophobic compounds. J Am Chem Soc 2003, 125: 15485–15489.
21 Bourne, N, Stanberry, LR, Kern, ER, Holan, G, Matthews, B,
et al. Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob Agents Chemother 2000, 44: 2471–2474.
22 Hollins, AJ, Benboubetra, M, Omidi, Y, Zinselmeyer, BH, Schatzlein, AG,
et al. Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor. Pharm Res 2004, 21: 458–466.
23 Wang, SJ, Brechbiel, M, Wiener, EC. Characteristics of a new MRI contrast agent prepared from polypropyleneimine dendrimers, generation 2. Invest Radiol 2003, 38: 662–668.
24 Majoros, IJ, Myc, A, Thomas, T, Mehta, CB, Baker, JR
Jr. PAMAM dendrimer‐based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 2006, 7: 572–579.
25 Majoros, IJ, Thomas, TP, Mehta, CB, Baker, JR
Jr. Poly(amidoamine) dendrimer‐based multifunctional engineered nanodevice for cancer therapy. J Med Chem 2005, 48: 5892–5899.
26 Patri, AK, Kukowska‐Latallo, JF, Baker, J, James, R. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non‐covalent drug inclusion complex. Adv Drug Deliv Rev 2005, 57: 2203–2214.
27 Patri, AK, Majoros, IJ, Baker, JR. Dendritic polymer macromolecular carriers for drug delivery. Curr Opin Chem Biol 2002, 6: 466–471.
28 Majoros, IJ, Keszler, B, Woehler, S, Bull, T, Baker, JR. Acetylation of poly(amidoamine) dendrimers. Macromolecules 2003, 36: 5526–5529.
29 Hong, SP, Bielinska, AU, Mecke, A, Keszler, B, Beals, JL,
et al. Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. Bioconjug Chem 2004, 15: 774–782.
30 Hong, SP, Leroueil, PR, Janus, EK, Peters, JL, Kober, MM,
et al. Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability. Bioconjug Chem 2006, 17: 728–734.
31 Leroueil, PR, Hong, SY, Mecke, A, Baker, JR, Orr, BG,
et al. Nanoparticle interaction with biological membranes: does nanotechnology present a janus face? Acc Chem Res 2007, 40: 335–342.
32 Goodwin, AP, Lam, SS, Frechet, JM. Rapid, efficient synthesis of heterobifunctional biodegradable dendrimers. J Am Chem Soc 2007, 129: 6994–6995.
33 Backer, MV, Gaynutdinov, TI, Patel, V, Bandyopadhyaya, AK, Thirumamagal, BTS,
et al. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther 2005, 4: 1423–1429.
34 Patri, AK, Myc, A, Beals, J, Thomas, TP, Bander, NH,
et al. Synthesis and
in vitro testing of J591 antibody‐dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem 2004, 15: 1174–1181.
35 Shukla, R, Thomas, TP, Peters, JL, Desai, AM, Kukowska‐Latallo, J,
et al. HER2 specific tumor targeting with dendrimer conjugated anti‐HER2 mAb. Bioconjug Chem 2006, 17: 1109–1115.
36 Thomas, TP, Patri, AK, Myc, A, Myaing, MT, Ye, JY,
et al. In vitro targeting of synthesized antibody‐conjugated dendrimer nanoparticles. Biomacromolecules 2004, 5: 2269–2274.
37 Wu, G, Barth, RF, Yang, WL, Chatterjee, M, Tjarks, W,
et al. Site‐specific conjugation of boron‐containing dendrimers to anti‐EGF receptor monoclonal antibody cetuximab (IMC‐C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconjug Chem 2004, 15: 185–194.
38 Wu, G, Barth, RF, Yang, WL, Kawabata, S, Zhang, LW,
et al. Targeted delivery of methotrexate to epidermal growth factor receptor‐positive brain tumors by means of cetuximab (IMC‐C225) dendrimer bioconjugates. Mol Cancer Ther 2006, 5: 52–59.
39 Shukla, R, Thomas, TP, Peters, J, Kotlyar, A, Myc, A,
et al. Tumor angiogenic vasculature targeting with PAMAM dendrimer‐RGD conjugates. Chem Commun (Camb) 2005, 46: 5739–5741.
40 Lesniak, WG, Kariapper, MS, Nair, BM, Tan, W, Hutson, A,
et al. Synthesis and characterization of PAMAM dendrimer‐based multifunctional nanodevices for targeting alphavbeta3 integrins. Bioconjug Chem 2007, 18: 1148–1154.
41 Sheng, KC, Kalkanidis, M, Pouniotis, DS, Esparon, S, Tang, CK,
et al. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity
in vitro and
in vivo. Eur J Immunol 2008, 38: 424–436.
42 Baek, MG, Roy, R. Synthesis and protein binding properties of T‐antigen containing GlycoPAMAM dendrimers. Bioorg Med Chem 2002, 10: 11–17.
43 Taite, LJ, West, JL. Poly(ethylene glycol)‐lysine dendrimers for targeted delivery of nitric oxide. J Biomater Sci Polym Ed 2006, 17: 1159–1172.
44 Kono, K, Liu, M, Frechet, JM. Design of dendritic macromolecules containing folate or methotrexate residues. Bioconjug Chem 1999, 10: 1115–1121.
45 Shukla, S, Wu, G, Chatterjee, M, Yang, W, Sekido, M,
et al. Synthesis and biological evaluation of folate receptor‐targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. Bioconjug Chem 2003, 14: 158–167.
46 Thomas, TP, Majoros, IJ, Kotlyar, A, Kukowska‐Latallo, JF, Bielinska, A,
et al. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem 2005, 48: 3729–3735.
47 Myc, A, Douce, TB, Ahuja, N, Kotlyar, A, Kukowska‐Latallo, J,
et al. Preclinical antitumor efficacy evaluation of dendrimer‐based methotrexate conjugates. Anticancer Drugs 2008, 19: 143–149.
48 Myc, A, Majoros, IJ, Thomas, TP, Baker, JR. Dendrimer‐based targeted delivery of an apoptotic sensor in cancer cells. Biomacromolecules 2007, 8: 13–18.
49 Myc, A, Patri, AK, Baker, JR. Dendrimer‐based BH3 conjugate that targets human carcinoma cells. Biomacromolecules 2007, 8: 2986–2989.
50 Landmark, KJ, DiMaggio, S, Ward, J, Kelly, C, Vogt, S,
et al. Synthesis, characterization, and
in vitro testing of superparamagnetic iron oxide nanoparticles targeted using folic acid‐conjugated dendrimers. ACS Nano 2008, 2: 773–783.
51 Quintana, A, Raczka, E, Piehler, L, Lee, I, Myc, A,
et al. Design and function of a dendrimer‐based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 2002, 19: 1310–1316.
52 Goyal, P, Yoon, K, Weck, M. Multifunctionalization of dendrimers through orthogonal transformations. Chemistry 2007, 13: 8801–8810.
53 Modi, S, Prakash Jain, J, Domb, AJ, Kumar, N. Exploiting EPR in polymer drug conjugate delivery for tumor targeting. Curr Pharm Des 2006, 12: 4785–4796.
54 Jain, RK. Delivery of molecular medicine to solid tumors: lessons from
in vivo imaging of gene expression and function. J Control Release 2001, 74: 7–25.
55 Jain, RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999, 1: 241–263.
56 Malik, N, Evagorou, EG, Duncan, R. Dendrimer‐platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 1999, 10: 767–776.
57 Bhadra, D, Bhadra, S, Jain, S, Jain, NK. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm 2003, 257: 111–124.
58 Chauhan, AS, Jain, NK, Diwan, PV, Khopade, AJ. Solubility enhancement of indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats. J Drug Target 2004, 12: 575–583.
59 Asthana, A, Chauhan, AS, Diwan, PV, Jain, NK. Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site‐specific delivery of acidic anti‐inflammatory active ingredient. AAPS PharmSciTech 2005, 6: E536–E542.
60 Leroueil, PR, Berry, SA, Duthie, K, Han, G, Rotello, VM,
et al. Wide varieties of cationic nanoparticles induce defects in supported lipid bilayers. Nano Lett 2008, 8: 420–424.
61 Malik, N, Wiwattanapatapee, R, Klopsch, R, Lorenz, K, Frey, H,
et al. Dendrimers: relationship between structure and biocompatibility
in vitro, and preliminary studies on the biodistribution of 125I‐labelled polyamidoamine dendrimers
in vivo. J Control Release 2000, 65: 133–148.
62 Jevprasesphant, R, Penny, J, Jalal, R, Attwood, D, McKeown, NB,
et al. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 2003, 252: 263–266.
63 Roberts, JC, Bhalgat, MK, Zera, RT. Preliminary biological evaluation of polyamidoamine (PAMAM) starburst dendrimers. J Biomed Mater Res 1996, 30: 53–65.
64 Nigavekar, SS, Sung, LY, Llanes, M, El‐Jawahri, A, Lawrence, TS,
et al. 3H dendrimer nanoparticle organ/tumor distribution. Pharm Res 2004, 21: 476–483.
65 Kobayashi, H, Kawamoto, S, Saga, T, Sato, N, Hiraga, A,
et al. Positive effects of polyethylene glycol conjugation to generation‐4 polyamidoamine dendrimers as macromolecular MR contrast agents. Magn Reson Med 2001, 46: 781–788.
66 Ihre, HR, Padilla De Jesus, OL, Szoka, FC
Jr, Frechet, JM. Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization. Bioconjug Chem 2002, 13: 443–452.
67 Heiden, TC, Dengler, E, Kao, WJ, Heideman, W, Peterson, RE. Developmental toxicity of low generation PAMAM dendrimers in zebrafish. Toxicol Appl Pharmacol 2007, 225: 70–79.
68 Kukowska‐Latallo, JF, Bielinska, AU, Johnson, J, Spindler, R, Tomalia, DA,
et al. Efficient transfer of genetic material into mammalian cells using starburst polyamidoamine dendrimers. Proc Natl Acad Sci U S A 1996, 93: 4897–4902.
69 Tang, MX, Redemann, CT, Szoka, FC
Jr. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug Chem 1996, 7: 703–714.
70 Haensler, J, Szoka, FC
Jr. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem 1993, 4: 372–379.
71 Sonawane, ND, Szoka, FC
Jr, Verkman, AS. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine‐DNA polyplexes. J Biol Chem 2003, 278: 44826–44831.
72 Shi, X, Wang, SH, Shen, M, Antwerp, ME, Chen, X,
et al. Multifunctional dendrimer‐modified multiwalled carbon nanotubes: synthesis, characterization, and
in vitro cancer cell targeting and imaging. Biomacromolecules 2009, 10: 1744–1750.
73 Wilbur, DS, Pathare, PM, Hamlin, DK, Buhler, KR, Vessella, RL. Biotin reagents for antibody pretargeting. 3. synthesis, radioiodination, and evaluation of biotinylated starburst dendrimers. Bioconjug Chem 1998, 9: 813–825.
74 Langereis, S, de Lussanet, QG, van Genderen, Marcel, HP, Backes, WH, Meijer, EW. Multivalent contrast agents based on Gadolinium‐Diethylenetriaminepentaacetic acid‐terminated poly(propylene imine) dendrimers for magnetic resonance imaging. Macromolecules 2004, 37: 3084–3091.
75 Yang, W, Barth, RF, Wu, G, Bandyopadhyaya, AK, Thirumamagal, BT,
et al. Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas. Appl Radiat Isot 2004, 61: 981–985.
.jpg)
